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Summary The p53 tumour-suppressor gene is important in the regulation of cell growth and apoptosis, and loss of functional wild-type
activity may be associated with tumourformation and resistance to therapy. Differentiation offunctionally normal wild-type protein from mutant
orabnormal protein remains difficult using either immunohistochemical assays or mutational DNA sequencing. p21WAFl/ClPl (p21) is induced by
wild type p53 and plays an important role in promoting cell cycle arrest. To test the hypothesis that p21 protein expression may act as a
downstream marker of tumours from patients with locally advanced breast cancer before treatment with doxorubicin, pretreatment p53 status
had been characterized in 63 tumours by p53 protein immunostaining and DNA mutational analysis. There was a significant association
between immunostaining for p53 and the presence of p53 mutations (P= 0.01). Of 56 patients available for determination of p21, 31 (55%)
expressed p21 protein. Twenty-eight out of 31 patients (90%) positive for p21 had low negative p53 protein expression, whereas only 3 of 13
patients (23%) with high p53 expressed p21 (P = 0.009). No association was seen between p21 protein expression and p53 mutations
(P= 0.24). The combination of p53 and p21 immunostaining results improved the specificity of the immunostaining but at a cost of significant
reduction in sensitivity. Immunohistochemical assessment of p21 protein expression is inversely associated with abnormal p53 protein in
human breast cancer. The detection of p21 protein expression in combination with p53 protein expression did not improve the ability of
immunohistochemistry (IHC) to differentiate between normal and mutant p53 protein.
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The p53 tumour-suppressor gene encodes for a 393 amino acid
nuclear protein that functions as a transcription factor important in
the detection and repair of DNA damage (Kastan et al, 1991).
Following induction of a genotoxic stress, wild-type p53 protein
levels are elevated, either leading to cell cycle arrest inGI (Lin et
al, 1992), allowing DNA repair to take place, or, if DNA damage
is extensive, triggering of cell death by apoptosis (Lowe et al,
1993). p53 is the most commonly mutated gene in human cancer,
and loss ofwild-type activity may be important both in the devel-
opment of tumours, including breast cancer (Greenblatt et al,
1994), and in impairing the response of cells to cancer therapy
(Lowe, 1995).
p53 has been extensively studied in human breast cancer, with
reported mutation rates in untreated tumours varying between 15%
and 50%, depending on the detection method used (Andersen and
Borresen, 1995). The most commonly used method to detect p53
alterations is immunohistochemistry (IHC), its underlying prin-
ciple being that mutated abnormal protein, unlike wild-type
protein, has a prolonged half-life, leading to accumulation in the
nucleus that can be detected in approximately 30-50% of breast
cancers (Elledge and Allred, 1994). DNA-based methods, such as
single-strand conformation polymorphism analysis (SSCP) or
constant denaturant gel electrophoresis (CDGE), detect fewer
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alterations (15-40%) (Andersen and Borresen, 1995). Reasons for
this discrepancy include the fact that mutated p53 may not be
detected by IHC if a deletion or stop mutation occurs. Non-
mutated protein may be detected by IHC if it has been stabilized
by other factors such as mdm-2 (Wu et al, 1993) or viral proteins
(Levine et al, 1991), which may render it non-functional, or DNA
damage, which may lead to stabilization of normal wild-type
protein (Hall et al, 1993). DNA-based methods may not detect a
mutation ifit occurs in an exon outside those screened by the tech-
nique. Thus, although IHC is relatively inexpensive, easily applied
to large numbers of samples and remains an important method for
detecting p53 alterations it is currently not able to differentiate
mutant from normal protein. The identification of a reliable
marker of wild-type p53 protein would therefore be an important
advance in this field.
Following DNA damage, wild-type p53 transcriptionally
induces a number ofgenes, including the cyclin-dependent kinase
(cdk) inhibitor p21 (El-Deiry et al, 1993). The p21 protein medi-
ates theGI arrest induced by p53 in response to DNA damage by
associating with a cyclin/cdk/PCNA complex and causing inhibi-
tion ofits kinase activity, thus blocking cell cycle progression into
S-phase (Waldman et al, 1995). This process cannot occur without
p21 (Waldman et al, 1995) and cannot be induced by mutant p53
(El-Diery et al, 1994). The identification of p21 as a critical
effector of wild-type p53 in the growth arrest pathway raises the
possibility ofusing p21 expression as a marker offunctional wild-
type p53 activity in vivo. The development of monoclonal anti-
bodies to the p21 protein (El-Diery et al, 1995) has allowed us to
study this relationship at the protein level.
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In this study we report on the relationship between p21 protein
expression and p53 status, as characterized by both IHC and muta-
tional analysis, before and after treatment of 63 primary breast
cancer patients receiving anthracycline chemotherapy The aims of
the study were to determine (1) whether an association between p21
expression and wild-type p53 exists in human breast cancer and (2)
whether the expression of p21 could be useful in distinguishing
normal from immunohistochemically detected mutant p53.
MATERIALS AND METHODS
Patients and tissue samples
Sixty-three patients with histologically proven locally advanced
breast cancer were treated at Haukeland University Hospital with
single-agent doxorubicin. All patients were UICC stage T3/T4
and/or N2, with seven patients having concomitant solitary distant
metastases. Median age was 64 years (range 32-85 years). Before
treatment an open biopsy was performed, part of which was snap-
frozen and stored in liquid nitrogen, the remainder being fixed in
formalin soon after removal and paraffin embedded. Patients
received doxorubicin 14 mg m-2 weekly for 16 weeks before local
therapy (either surgery and/or radiotherapy). Tumour size was
assessed bidimensionally before each cycle of chemotherapy, and
clinical response was determined according to standard UICC
criteria (Hayward et al, 1977). Post-treatment samples were
obtained following surgery and divided and stored as described
above. The study was approved by the regional ethics committee.
p53 status
p53 status had previously been determined on this group ofpatients
by immunostaining forp53 protein andby DNA mutational analysis,
and analysed in relation to clinical response (Aas et al, 1996).
Immunohistochemistry
This was performed on formalin-fixed paraffin-embedded material
using the avidin-biotin complex method (Hsu et al, 1981) with the
DO-7 antibody (Dako) at a dilution of 1:100 with incubation at
room temperature for 1 h after microwave pretreatment of the
slides. Nuclear staining was recorded using a semiquantitative
grading, taking into account both staining intensity and proportion
of positive tumour cells. Intensity was recorded as 0 (no staining)
to 3 (strong staining) and the percentage of cells positive as 0 (no
cells positive), 1 (< 10% positive), 2 (10-50% positive) or 3
(> 50% positive). A staining index was then calculated as the
product ofstaining intensity and proportion ofpositive cells with a
score of 2 or greater considered positive. A high p53 staining
index was defined as a score of 6-9.
Mutationalanalysis
Mutations in the p53 gene were analysed by constant denaturant
gel electrophoresis (CDGE) (Borresen et al, 1991), with primers
covering the evolutionary conserved regions of the gene, exons
5-8 (codons 126-300). The PCR products of all samples with
aberrant migrating bands on CDGE were submitted to direct
sequencing of PCR products with standard dideoxy sequencing
Figure 1 Immunohistochemical expression of p21 protein breast carcinoma
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reaction and Dynabeads M280-Streptavidin (Dynal, Norway).
mRNA was prepared by QuickPrep Micro Purification Kit
(Pharmacia Biotech) on all patients with progressive disease (PD)
(n = 6), and on ten randomly selected patients withnegative results
on CDGE. This was followed by cDNA synthesis using the Gene
Amp RNA-PCR Core Kit (Perkin Elmer). Sequencing of the
cDNA products was performed using the Dye Terminator Cycle
Sequencing Kit with AmpliTag FS on an ABI 373 sequencer
(Perkin Elmer).
p21 status
Sections (3, m) were dewaxed, rehydrated with water, then placed
in 300 ml of citrate buffer and heated twice for 5 min each in a
microwave oven at 750 W and allowed to cool. After the addition
ofnormal rabbit serum, the sections were incubated with theWAF-
1 (Calbiochem) monoclonal antibody at a 1:100 dilution for 1 h.
Slides were then incubated successively with biotinylated rabbit
anti-mouse antibody (Dako) and the avidin-biotinylated horse-
radish peroxidase complex (ABC) (Dako) (Hsu et al, 1981), devel-
oped with diaminobenzidine (DAB) (Sigma) and counterstained
with haematoxylin. All washes were with phosphate-buffered
saline (PBS), and incubations were carried out at room tempera-
ture. p21 score was defined as the percentage oftumour cells with
positive nuclei (Figure 1). A section from a breast carcinoma with
previously established positivity was included as a positive
control, and a breast carcinoma section without the primary anti-
body acted as a negative control in all batches.
For all immunohistochemical assays sections were coded and
scored blind to treatment outcome using a standard light micro-
scope. At least 1000 cells were counted in high-powered field
(x 400 objective) spread randomly throughout the section and
away from areas ofnecrosis.
Table 1 IHC p53 and p21 scores for patients with proven mutations
Mutation type Affecting L2/L3a p53 indexb p21 score (%)
Nonsense/splice
1 + 9 0
2 + 1 0
3 + 0 2
Missense/deletions
4 - 6 0
5 + 9 0
6 + 1 0
7 + 0 3
8 + 9 0
9 + 6 0
10 - 6 7
11 + 1 2
12 + 0 2
13 + 9 46
14 - 6 0
15 - 4 7
16 9 0
17 - 6 0
aL2/L3, L2/L3 DNA binding domain of p53 protein; bp53 staining index,
nuclear staining intensity x proportion of positive tumour cells. Intensity was
recorded as 0 (no staining) to 3 (strong staining) and percentage of cells
positive as 0 (no cells positive), 1 (< 10% positive), 2 (10-50% positive) or 3
(> 50% positive).
Statistical analysis
Statistical analysis was conducted with use ofthe BMDP software
(Dixon, 1985). Time to relapse (months) was recorded from time
ofterminating chemotherapy, and patient survival from the time of
histological diagnosis. Comparison between different groups was
performed by Fisher's exact test. Survival was estimated by the
product-limit method, and differences between groups of patients
were analysed by the log-rank test. The influence of combined
p53/p2l immunostaining phenotype on clinical response was
determined in a multivariate analysis using logistic regression.
RESULTS
p53 status
The p53 status of this group of patients has been reported previ-
ously (Aas et al, 1996). Eighteen of 63 patients (29%) had muta-
tions in the p53 gene when evaluated by CDGE (16 patients), or
direct sequencing of cDNA (two patients). Twenty-six patients
(41%) were positive forp53 by IHC, ofwhom 14 (22%) showed a
high p53 staining index (2 6). There was a significant association
between positive staining for p53 and the presence of p53 muta-
tions (P = 0.01, Fisher's exact test), which was much stronger
when only patients with high p53 were considered (P < 0.00005).
Relationship of pretreatment p21 status to p53
Sufficient material was available forp21 immunostaining on 56 of
63 (88%) patients of whom 17 had documented p53 mutations
(Table 1). Thirty-one (55%) were positive for p21 protein expres-
sion (0-46.6% cells positive). Nineteen of the 31 p21-positive
tumours (62%) were IHC negative for p53, whereas 12 of 24
(50%) tumours IHC positive for p53 expressed p21 protein (P =
0.59). Of the 12 p21-positive tumours that were also positive for
p53, only three (25%) had ahighp53 staining index, whereas 10of
25 p21-negative tumours had a highp53 staining index. There was
a strong inverse association of p21 protein expression with high
p53 staining index (P = 0.009) (Table 2).
There was no statistical evidence for an inverse association
between p21 protein expression and presence of a p53 mutation.
Although 24 of31 (77%) p21-positive tumours lacked a mutation,
so did 15 of 25 (60%) p21-negative tumours (P = 0.24) (Table 2).
The combination of both p53 mutational status and high p53
staining index to provide a single indicative measure of p53
protein alteration again showed no statistically significant inverse
association with p21 protein expression (P = 0.15) (Table 2).
Table 2 Relationship between p21 immunostaining and p53 alteration
Staininga,* Mutationb,** Staining mutationc,***
p53+ p53- p53+ p53- p53' p53-
p21+ 3 28 7 24 8 23
p21- 10 15 10 15 12 13
ap53 positive = IHC staining index 6-9; bp53 positive = mutation (determined
by CDGE and/or DNA sequencing); cp53 positive = IHC staining index 6-9
and/or mutation (determined by CDGE and/or DNA sequencing. *P = 0.009;
**P= 0.24; ***P= 0.11.
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Table 3 Effect of combining p53 and p21 on sensitivity and specificity of
immunostaining compared with p53 immunostaining alone
IHC status p53 mutational status
Mutation No mutation
p53+ 11 13
p53- 6 26
Sensitivity 11/17 (65%)
Specificity 26/39 (67%)
p53+/p21- 8 4
p53+/p21- (3) (9)
p53-/p21- (2) 9 (11) 35
p53-/p21 + (4) (15)
Sensitivity 8/17 (47%)
Specificity 35/39 (90%)
Only p53+/p21- tumours considered as indicative of aberrant p53 function.
Value of combining p21 and p53 IHC
In this study, 26 out of 39 patients without a mutation were p53
IHC negative giving a specificity (i.e. correctly identifying those
without a mutation) of 67% (95% CI 48-79%), whereas 11 of 17
patients with a mutation were IHC positive giving a sensitivity
(correctly identifying those with a mutation) of 65% (95% CI
38-86%) (Table 3).
With regard to p21 status, 24 of 39 tumours (62%) without p53
mutations were IHC p21 positive, including nine who were IHC
p53 positive. Ten of 17 tumours (59%) with p53 mutations were
p21 IHC negative. Ifabnormal p53 protein is defined as excluding
those tumours with p53+/p2l+ phenotype, the specificity of
immunostaining is improved to 90% (35 of 39 tumours correctly
identified as being without a mutation) (95% CI 73-96%),
however this is at the cost of a marked reduction in sensitivity to
47% (8 of 17 tumours correctly identified as having a mutation)
(95% CI 20-70%) (Table 3). Thus, the use ofp21 protein expres-
sion in combination with p53 protein expression did not improve
the ability of IHC to predict p53 mutational status over p53 IHC
alone (Table 3).
Relationship of pretreatment 21 and p53 levels to
clinical response and outcome
Pretreatment p21 protein expression was not significantly associ-
ated with response to chemotherapy, time to relapse or overall
survival.
Response to therapy in four groups of patients according to
combined p2l/p53 immunostaining phenotype was also analysed
in a multivariate analysis using logistic regression. Response rate
for the following groups was as follows: p53+/p21+ = 58%;
p53-/p21+ = 42%; pS3+/p2l-= 58%; pS3-/p2l-= 38%. There was
no significant relationship between p21/p53 phenotype and clin-
ical response (P > 0.5).
DISCUSSION
The p53 tumour-suppressor gene plays an important role in cell
surveillance and is an integral partofthe processes ofgrowth arrest
and apoptosis that may occur following DNA damage (Kastan et
al, 1991; Lowe et al, 1993). It is frequently mutated in breast
cancer and recent reports have suggested specific p53 mutations to
be associated with impaired response to chemotherapy (Aas et al,
1996) and poor overall survival (Borresen et al, 1995). Accurate
measurement of the functional status of the protein, however,
remains difficult. The cyclin-dependent kinase inhibitor p21 has
been shown in vitro to be a downstream effector of wild-type p53
(El-Diery et al, 1994; Waldman et al, 1995) and is a candidate
marker offunctional p53 protein activity in vivo.
A number of studies have examined the relationship between
p53 and p21 in human tumours with conflicting results. There
have been two previous studies addressing this issue in human
breast cancer. Ozcelik et al (1995) demonstrated a negative corre-
lation between the presence of p53 mutations and p21 mRNA
expression in a series of primary breast cancers. Barbareschi et al
(1996) have very recently reported on immunohistochemical
expression ofp21 in 91 breast carcinomas, showing no association
with p53 protein expression. The relationship between p53 and
p21 has also been assessed in other tumour types. Thirty-five
patients with thyroid carcinomas were assessed immunohisto-
chemically forp53 andp21 protein, and with CDGE forp53 muta-
tion. Four of five patients with documented p53 mutations had
absent ormarkedly reducedp21 immunostaining, whereas the vast
majority ofpatients (90%) with wild-type p53 showed moderate to
strong expression of p21 (Zedenius et al, 1996). Elbendary et al
(1996) have reported a correlation between p53 gene and p21
expression in 23 primary epithelial ovarian cancers. Normal levels
ofp21 mRNA were seen in four out of seven (57%) cancers with
wild-type p53, whereas 14 out of 16 (88%) cancers with mutant
p53 had reduced p21 expression (P < 0.05). In contrast, Slebos et
al (1996) found no association between p53 inactivation (detected
by both denaturant gradient gel electrophoresis and immunohisto-
chemistry) and p21 protein expression in a group of 46 colorectal
carcinomas.
In this study we report an inverse relationship between p53
immunostaining and p21 protein expression. This was not
apparent when all p53-positive tumours were considered
abnormal, but was clearly seen when a high p53 staining index
(2 6) was analysed as indicative of an abnormal protein. There is
some evidence that a high p53 staining index predicts for a worse
clinical outcome and may predict better for mutated protein, but
this is by no means generally accepted (Allred et al, 1993; Barnes
et al, 1993). In our study, p53 mutational status as detected by a
DNA based method (CDGE) did not identify an inverse associa-
tion with p21, and although the combination of the two p53
analyses identified a trend this was not statistically significant.
This discrepancy between the relationships was predominantly due
to a number of patients (nos. 3, 11, 12, 15) with a documented
mutation who werep21 positive, butwho were negative orhad low
levels ofp53 protein expression on IHC. It is possible that in some
of these patients, particularly those with mutations outside the
L2/L3 domain, p53 protein may have been functionally normal.
The identification ofp53 protein accumulating in normal skin in
a time-dependent manner after UV irradiation suggested that wild-
type p53 can be identified by immunohistochemistry after DNA
damage (Hall et al, 1993). The increasing use ofchemotherapy for
breast cancer allows changes to be measured in parameters such as
p53 after chemotherapy and thus provides an opportunity to gain
insight into its role in tumour response to chemotherapy in vivo.
However, this requires the ability to differentiate functionally
normal wild-type protein from mutantprotein. Recently, immuno-
histochemical identification of the p21 protein has shown it to be
up-regulated in human skin after UV radiation-induced damage in
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a manner consistent with its regulation by p53 (El-Diery et al,
1995). Our second major aim in this study was to determine
whether the combinations of p21 and p53 immunostaining in a
population of tumours in which p53 mutation status was known
might enable us to better differentiate between wild-type and
mutant protein compared with p53 IHC alone.
In agreement with other studies (Elledge and Allred, 1994), IHC
evaluation of p53 protein expression in our study showed only
moderate sensitivity and specificity in correctly identifying those
patients with or without ap53 mutation. The addition ofp21 to p53
did improve the specificity of immunostaining (to correctly iden-
tify those patients without amutation), howeverthis was atthe cost
of a marked fall in the sensitivity of the test. As discussed above,
whereas the presence of a mutation in some parts of the gene may
not prevent the formation of functional protein, a number of these
patients (e.g. patients 3, 7, 11, 12, 13; Table 1) with p21 protein
expression had mutations affecting theLA3 DNA-binding orzinc-
binding domains of the protein, which almost certainly impair
function (Borresen et al, 1995). Other patients with a pS3+/p2l-
phenotype without mutation could suggest a situation in which
high p53 expression is related to functional inactivation by non-
mutational events leading to p53 stabilization.
Overall, these data suggest the presence of in vivo mechanisms
independent of p53 for induction of p21. They also indicate that
p21 cannot be used alone as a marker for functional wild-type p53
activity. Although p21 had been shown in vitro to be induced by
alternative p53-independent pathways during normal cell growth
response following mitogens (Michieli et al, 1994) and during
induction of differentiation (Jiang et al, 1994; Steinman et al,
1994; Parker et al, 1995), it had been thought that wild-type p53
was still required for the induction of p21 in DNA-damaged cells
(El-Diery et al, 1994; Michieli et al, 1994). Two recent studies
have, however, unequivocally shown p21 to be induced indepen-
dently of p53 following exposure to DNA-damaging agents
(Johnson et al, 1994; Sheikh et al, 1994).
Although not a primary aim ofthis study, the assessment ofp21
immunostaining alone and/orthe p2l/pS3 phenotype as apredictor
of clinical response and outcome is of interest. In this series,
neitherp21 immunostaining alone northe combination ofp21/p53
phenotype was significantly associated with clinical response or
disease-free or overall survival. Two other larger studies designed
to study this question have reported preliminary data suggesting
that p21 expression may be of prognostic value, and possibly
useful as a predictive factor for clinical outcome after systemic
therapy. In a series of 91 primary breast carcinomas, Barbareschi
et al (1996) reported high p21 expression to be significantly asso-
ciated with shortened relapse-free survival. Caffo et al (1996), also
report, in a series of261 primary breast carcinomas, that p21 over-
expression was associated with a shortened disease-free survival
(DFS), particularly in node-negative patients (P = 0.003). In
patients treated with systemic adjuvant therapy, bivariate analysis
of the combined p21 and p53 phenotypes showed that patients
with p2l-/pS3+ were found to have the worst prognosis.
Multivariate analysis confirmed the p21-/p53+ phenotype as inde-
pendently associated with shorter DFS and overall survival.
In conclusion, in this study we have demonstrated immunohisto-
chemically that p21 protein is expressed in human breast cancer
and is inversely associated with p53 immunostaining. It is possible
that a high p53 staining index using IHC is a better predictor ofthe
functional state of the p53 protein than DNA-based mutational
analysis. However, our data support recent in vitro data suggesting
that there are p53-independent pathways thatregulate p21. Overall,
p21 immunostaining was not useful as an addition to p53 immuno-
staining in differentiating between normal and mutant p53 protein.
REFERENCES
Aas T, Borresen A, Geisler S, Johnsen H, Varhaug JE, Akslen LA and Lonning PE
(1996) Specific TP53 gene mutation sare associated with de novo resistance to
doxorubicin breast cancer patients. Nature Med2: 811-814
Allred DC, Clark GM, Elledge RM, Fuqua SA, Brown RW, Chamness GC, Osborne
CK and McGuire WL (1993) Association ofp53 protein expression with
tumour cell proliferation rate and clinical outcome in node negative breast
cancer. JNatl Can Inst, 85: 200-206
Andersen T and Borresen A-L (1995) Alterations ofthe TP53 gene as a potential
prognostic marker in breast carcinomas. Diag Mol Pathol 4: 203-211
Barbareschi M, Caffo 0, Doglioni C, Fina P, Marchetti A, Buttita F, Leek R, Morelli
L, Leonardi E, Bevilacqua G, Dalla Palma P and Harris A (1996) p21 WAFI
immunohistochemical expression in breast carcinoma: correlations with
clinicopathological data, oestrogen receptor status, MIB-1 expression, p53 gene
and protein alterations and relapse-free survival. BrJ Cancer 74: 208-215
Barnes DM, Dublin EA, Fisher CJ, Levison DA and Millis RR (1993)
Immunohistochemical detection ofp53 protein in mammary carcinoma: An
important new independent indicator ofprognosis? Hum Pathol 24: 469-476
Borresen A-L, Hovig E, Smith-Sorensen B, Malkin D, Lystad S, Andersen TI,
Nesland JM, Isselbacher KJ and Friend SH (1991) Constant denaturant gel
electrophesis as a rapid screening technique for p53 mutations. Proc NatlAcad
Sci USA 88: 8405-8409
Borresen A-L, Andersen TI, Eyfjord JE, Comelis RS, Thorlacius S, Borg A,
Johansson U, Theillet C, Scherneck S, Hartmen S, Cornelisse CJ, Hovig E and
Devilee P (1995) TP53 mutations and breast cancer prognosis: Particularly
poor survival rates for cases with mutations in the zinc-binding domains. Genes
Chromosom Cancer 14: 71-75
Caffo 0, Doglioni C, Veronese S, Bonzanini M, Marchetti A, Buttitta F, Fina P, Leek
R, Morelli L, Dalla Parma P, Harris AL and Barbareschi M (1996) Prognostic
value ofp21 WAF-1 and p53 expression in breast carcinoma: An
immunohistochemical study in 261 patients with long-term followup. Clin
CancerRes 2: 1591-1599
Dixon WJ (1985) BMDP statistical software. University ofCalifornia Press:
California
El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D,
Mercer WE, Kinzler KW and Vogelstein B (1993). WAF1, a potential mediator
ofp53 tumour suppression. Cell 75: 817-825
El-Diery WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J,
Pietenpool JA, Burrell M, Hill DE, Wang Y, Winman KG, Mercer WE, Kastan
MB, Kohn K, Elledge SJ, Kinzler KW and Vogelstein B (1994) WAFI/CIPI is
induced in p53-mediated GI arrest and apoptosis. CancerRes 54: 1169-1174
El-Diery WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell M, Hill DE,
Healy E, Rees JL, Hamilton SR, Kinzler KW and Vogelstein B (1995)
Topological control ofp21(WAFI/CIPI) expression in normal and neoplastic
tissues. CancerRes 55: 2910-2919
Elbendary AA, Cirisano FD, Evans AC, Davis PL, Iglehart JD, Marks JR and
Berchuck A (1996) Relationship between p21 expression and mutation ofthe
p53 tumour suppressor gene in normal and malignant ovarian epithelial cells.
Clin Cancer Res 2: 1571-1575
Elledge RM and Allred DC (1994) The p53 tumor suppressor gene in breast cancer.
Breast Cancer Res Treat32: 39-47
Greenblatt MS, Bennett WP, Hollstein M and Harris CC (1994) Mutations in the p53
tumour suppressor gene: clues to canceretiology and molecular pathogenesis.
Cancer Res 54: 4855-4878
Hall PA, McKee PH, Menage HD, Dover R and Lane DP (1993) High levels ofp53
protein in UV irradiated normal skin. Oncogene 8: 203-207
Hayward JL, Carbone PP and Heudson JC (1977) Assessment ofresponse to therapy
in advanced breast cancer. EurJ Cancer 13: 89-94
Hsu SM, Raine L and Fanger H (1981) Use ofthe avidin-biotin-peroxidase complex
(ABC) and unlabelled antibody (PAP) procedure. JHistochem Cytochem 29:
577-580
Jiang H, Lin J, Su ZZ, Collart FR, Huberman E and Fisher PB (1994) Induction of
differentiation in human promyelocytic HL-60 leukaemia cells activates p21
WAFI/CIPl expression in the absence ofp53. Oncogene 9: 3397-3406
Johnson M, Dimitrov D, Vojta PJ, Barrett JC, Noda A, Pereira-Smith OM and Smith
JR (1994) Evidence for ap53-independent pathway forupregulation of
SD11/CIPl/WAF1/p21 RNA in human cells. Mol Carcinogen 11: 59-44
British Journal ofCancer(1997) 76(4), 480-485 0CancerResearch Campaign 1997P21 andp53 expression in breast carcinomas 485
Kastan MB, Onyekwere 0, Sidransky D, Vogelstein B and Craig RW (1991)
Participation ofp53 protein in the cellular response to DNA damage. Cancer
Res 51: 6304-6311
Levine AJ, Momand J and Finlay CA (1991) The p53 tumour suppressor gene.
Nature 351: 453-456
Lin D, Shields MT, Ullrich SJ, Appella E and Mercer WE (1992) Growth arrest
induced by wild type p53 protein blocks cells prior to or near the restriction
point in late G1 phase. Proc NatlAcadSci 89: 9210-9214
Lowe SW (1995) Cancer therapy and p53. Curr Opin Oncol 7: 76-82
Lowe SW, Schmitt EM, Smith SW, Osbome BA and Jacks T (1993) p53 is required
for radiation induced apoptosis in mouse thymocytes. Nature 362: 847-852
Michieli P, Chedid M, Lin D, Pierce JH, MercerWE and Givol D (1994) Induction
ofWAFl/CIPl by a p53 independent pathway. CancerRes 54: 3391-3395
Ozcelik H, Mousses S and Andrulis IL (1995) Low levels ofexpression ofan
inhibitor ofcyclin-dependent kinases (CIPl/WAFl) in primary breast
carcinomas with p53 mutations. Clin CancerRes 1: 907-912
Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, Olson EN, Harper
JW and Elledge SJ (1995) p53-independent expression ofp21 CIPI in muscle
and other terminally differentiating cells. Science 267: 1024-1027
Sheikh MS, Li XS, Chen JC, Shao ZM, Ordonez JV and Fontana JA (1994)
Mechanisms ofregulation ofWAFI/Cipl gene expression in human breast
carcinoma: role ofp53-dependent and independent signal transduction
pathways. Oncogene 9: 3407-3415
Slebos RJC, Baas 10, Clement M, Polak M, Mulder J-W, vanden Berg FM,
Hamilton SR and Offerhaus GJA (1996) Clinical and pathological associations
with p53 tumour-suppressor gene mutations and expression ofp21 WAFl/CIP1
in colorectal carcinoma. BrJ Cancer74: 165-171
Steinman RA, Hoffman B, Iro A, Guillouf C, Lieberman DA and El-Houseini ME
(1994) Induction ofp21 (WAFI/CIPI) during differentiation. Oncogene 9:
3389-3396
Waldman T, Kinzler K and Vogelstein B (1995) p21 is necessary for p53-mediated
GI arrest in human cancer cells. CancerRes 55: 5187-5190
Wu X, Boyle JH, Olson DC and Levine AJ (1993) The p53-mdm2 autoregulatory
feedback loop. Genes Dev 7: 1126-1132
Zedenius J, Larsson C, Wallin G, Backdahl M, Aspenblad U, Hoog A, Borresen A-L
and Auer G (1996) Alterations ofp53 and expression ofWAF1/p21 in human
thyroid tumours. Thyroid 6: 1-9
C Cancer Research Campaign 1997 British Joural ofCancer (1997) 76(4), 480-485